Abstract The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid
leukemia, including in the more immature leukemic populations. Constitutive PI3K activation …

The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently
activated, representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 …

Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …

Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin
complex 1 (mTORC1) signaling pathways are frequently activated in acute myelogenous …

Technological advances allowing high throughput analyses across numerous cancer
tissues have allowed much progress in understanding complex cellular signaling. In the …

Despite recent advances in the field, the treatment of patients with acute myeloid leukemia
(AML) remains challenging and difficult. Although chemotherapeutic agents induce …

The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin
(PI3K/Akt/mTOR) pathway is amplified in 60–80% of patients with acute myelogenous …

Purpose: To determine whether mTORC2 and rapamycin-insensitive (RI)-mTORC1
complexes are present in acute myeloid leukemia (AML) cells and to examine the effects of …

It has become apparent that regulation of protein translation is an important determinant in
controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase …

Background: The PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays
a central role in cell growth, proliferation and survival not only under physiological …